Vaccination against RSV

  • Kaaijk P
  • Luytjes W
  • Rots N
N/ACitations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The respiratory syncytial virus (RSV) is the major cause of lower respiratory tract illness (LRI) in infants worldwide. Also persons with heart/lung disease or an immunodeficiency disorder, and the elderly are at increased risk for severe LRI upon RSV infection. Although there is at present no licensed RSV vaccine available, it is a priority target for several vaccine developers. For the implementation of a future RSV vaccination within national immunization schemes, various strategies can be considered even without the availability of extended clinical data on RSV vaccines. For this purpose, the extensive knowledge on RSV with respect to disease pathology, epidemiology and immunology can be used. This article discusses different aspects that should be considered to enable a successful implementation of a new RSV vaccine in national immunization programs. In addition, gaps in knowledge that needs further attention are identified. The maternal immunization strategy is highlighted, but also vaccination in t...

Cite

CITATION STYLE

APA

Kaaijk, P., Luytjes, W., & Rots, N. Y. (2013). Vaccination against RSV. Human Vaccines & Immunotherapeutics, 9(6), 1263–1267. https://doi.org/10.4161/hv.24096

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free